TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

VASOPRESSIN IN DEXTROSE 5%

VASOPRESSIN
Cardiovascular Approved 2024-02-09
Jump to: Indications Approvals Trials Competitors Similar Safety Patents
1
Indication
--
Phase 3 Trials
2
Years on Market

Details

Status
Prescription
First Approved
2024-02-09
Routes
INTRAVENOUS
Dosage Forms
SOLUTION

Companies

GLAND
Active Ingredient: VASOPRESSIN

VASOPRESSIN IN DEXTROSE 5% Approval History

Loading approval history...

What VASOPRESSIN IN DEXTROSE 5% Treats

2 indications

VASOPRESSIN IN DEXTROSE 5% is approved for 2 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Vasodilatory Shock
  • Hypotension
Source: FDA Label

Drugs Similar to VASOPRESSIN IN DEXTROSE 5%

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

VASOPRESSIN
VASOPRESSIN
2 shared
Dr. Reddy's
Shared indications:
Vasodilatory ShockHypotension
VASOPRESSIN IN SODIUM CHLORIDE 0.9%
VASOPRESSIN
2 shared
Baxter
Shared indications:
Vasodilatory ShockHypotension
ADRENACLICK
EPINEPHRINE
1 shared
IMPAX
Shared indications:
Hypotension
ADRENALIN
EPINEPHRINE
1 shared
PH HEALTH
Shared indications:
Hypotension
AKOVAZ
EPHEDRINE SULFATE
1 shared
EXELA PHARMA
Shared indications:
Hypotension
CORPHEDRA
EPHEDRINE SULFATE
1 shared
PH HEALTH
Shared indications:
Hypotension
EMERPHED
EPHEDRINE SULFATE
1 shared
NEXUS
Shared indications:
Hypotension
EPINEPHRINE (AUTOINJECTOR)
EPINEPHRINE
1 shared
Teva
Shared indications:
Hypotension
EPIPEN JR.
EPINEPHRINE
1 shared
Viatris
Shared indications:
Hypotension
LEVOPHED
NOREPINEPHRINE BITARTRATE
1 shared
Pfizer
Shared indications:
Hypotension
NOREPINEPHRINE BITARTRATE
NOREPINEPHRINE BITARTRATE
1 shared
Fresenius Kabi
Shared indications:
Hypotension
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
NOREPINEPHRINE BITARTRATE
1 shared
LONG GROVE PHARMS
Shared indications:
Hypotension
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
NOREPINEPHRINE BITARTRATE
1 shared
SAGENT
Shared indications:
Hypotension
PHENYLEPHRINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE
1 shared
MEITHEAL
Shared indications:
Hypotension
SYMJEPI
EPINEPHRINE
1 shared
ADAMIS PHARMS CORP
Shared indications:
Hypotension
XYLOCAINE W/ EPINEPHRINE
EPINEPHRINE
1 shared
Fresenius Kabi
Shared indications:
Hypotension
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

VASOPRESSIN IN DEXTROSE 5% FDA Label Details

Pro

Indications & Usage

Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. • Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: ANDA216963 → Label: DailyMed → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.